<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583553</url>
  </required_header>
  <id_info>
    <org_study_id>VS-UrineID</org_study_id>
    <nct_id>NCT04583553</nct_id>
  </id_info>
  <brief_title>Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients Using Vikor Scientific Urine-ID Testing Menu (IDTM) and Standard Laboratory Culture</brief_title>
  <acronym>VS-UrineID</acronym>
  <official_title>Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients Using Vikor Scientific Urine-IDTM and Standard Laboratory Culture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vikor Scientific</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vikor Scientific Urine-IDTM is a molecular analysis technology which provides pathogen&#xD;
      detection, quantification, and resistance gene identification. Urine-IDTM delivers its&#xD;
      results through the technology platform Antibiotic Stewardship program (ABXAssist™), which&#xD;
      provides results incorporating regional sensitivity and susceptibility patterns, medication&#xD;
      costs, antibiotic spectrum of activity, and FDA guidance. This product aims to deliver&#xD;
      prompt, patient-centered and value-based guidance to clinicians for antibiotic selection&#xD;
      within 24 hours of delivery to testing facility.&#xD;
&#xD;
      Proposed advantages of Vikor Scientific Urine-IDTM include:&#xD;
&#xD;
        -  Expeditious result (within 24 hours post-lab arrival)&#xD;
&#xD;
        -  Simultaneous detection of polymicrobial and monomicrobial infections&#xD;
&#xD;
        -  Identification of 49 most common antibiotic resistance genes&#xD;
&#xD;
        -  Provision of up-to-date regional sensitivity and susceptibility patterns&#xD;
&#xD;
        -  Provision of cost-sensitive treatment options and FDA guidance&#xD;
&#xD;
        -  Easy accessibility (mobile, web-portal and electronic health records Integration)&#xD;
&#xD;
      This utility of this technology has yet to be investigated in a clinical study and could&#xD;
      prove to be a viable alternative or adjunctive diagnostic tool to standard laboratory&#xD;
      culture. Standard laboratory culture can take up to 7 days to return pathogen identification&#xD;
      and antibiotic susceptibility, potentially delaying appropriate care and prolonging exposure&#xD;
      to inappropriate empiric antibiotics. Our study aims to analyze the ability Vikor Scientific&#xD;
      Urine-IDTM to improve time to identification of correct pathogen and accuracy of pathogen&#xD;
      identification when compared to standard laboratory culture.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Commercially available Vikor Scientific Urine-IDTM urine collection kits will be provided to&#xD;
      the University of Kansas Medical Center (KUMC) Department of Urology by Vikor Scientific.&#xD;
&#xD;
      Urine samples will be collected for both standard laboratory culture at KUMC Lab and&#xD;
      expedited delivery to Vikor Scientific Lab for Urine-IDTM analysis. Vikor Scientific will&#xD;
      cover all costs associated with sample delivery. If insufficient urine volume is collected&#xD;
      for both standard laboratory culture at KUMC Lab and Vikor Scientific Urine-IDTM, urine will&#xD;
      be preferentially used for standard laboratory culture at KUMC Lab.&#xD;
&#xD;
      Provider clinical decision making will be based on standard laboratory cultures and therapy&#xD;
      will not be adjusted based on Vikor Urine-IDTM results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if Vikor Scientific Urine-IDTM can identify pathogen (or absence thereof) causing post-TURBT or post-bacillus Calmette Guerin (BCG) cystitis in a timelier manner than standard laboratory culture.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine if Vikor Scientific Urine-IDTM provides concordant identification or urinary pathogen and antimicrobial sensitivity compared to standard laboratory culture in post-TURBT or post-BCG cystitis.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pathogens involved in post-TURBT and post-BCG Urinary Tract Infection (UTI) and their antibiotic susceptibility/resistance profile</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the prevalence of post-TURBT and post-BCG cystitis with no causative pathogenic organism</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Urinary Tract Infections</condition>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Vikor Scientific Urine-IDTM</intervention_name>
    <description>Urine samples will be collected for both standard laboratory culture at KUMC Lab and expedited delivery to Vikor Scientific Lab for Urine-IDTM analysis. Vikor Scientific will cover all costs associated with sample delivery. If insufficient urine volume is collected for both standard laboratory culture at KUMC Lab and Vikor Scientific Urine-IDTM, urine will be preferentially used for standard laboratory culture at KUMC Lab.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine Samples will be collected for study&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All study participants will be enrolled from KUMC hospital and clinics. A total of 175&#xD;
        participants will be recruited. Participants undergoing the study will be asked to submit&#xD;
        urine sample to KUMC Lab within 7 days of onset on cystitis symptoms. Urine sample will be&#xD;
        divided for use in standard laboratory culture and Vikor Scientific Urine-IDTM. Urine-IDTM&#xD;
        samples will be collected with kits provide by Vikor Scientific. Urine-IDTM kits will be&#xD;
        expedited to Vikor Scientific Lab immediately following collection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability of participant OR Legally Authorized Representative (LAR) to understand this&#xD;
             study, and participant or LAR willingness to provide informed consent.&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Diagnosis of Non-Muscle Invasive Bladder Cancer (NMIBC)&#xD;
&#xD;
          4. Onset of cystitis or UTI symptoms within 7 days of Transurethral Resection of the&#xD;
             Bladder Tumor (TURBT) or BCG installation&#xD;
&#xD;
          5. Ability to collect urine sample for analysis via standard laboratory culture and Vikor&#xD;
             Scientific Urine-IDTM&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability of participant OR Legally Authorized Representative (LAR) to understand this&#xD;
             study, and participant or LAR willingness provide informed consent&#xD;
&#xD;
          2. Age &lt;18 years&#xD;
&#xD;
          3. Diagnosis of Muscle-Invasive or metastatic bladder cancer&#xD;
&#xD;
          4. Onset of cystitis greater than 7 days following TURBT or BCG installation&#xD;
&#xD;
          5. Inability to provide sufficient urine for both standard laboratory culture and Vikor&#xD;
             Scientific Urine-IDTM&#xD;
&#xD;
          6. Current prophylactic antibiotic use.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katie Glavin</last_name>
    <phone>9135888721</phone>
    <email>kglavin@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medcial Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Katie Glavin</last_name>
      <phone>913-588-8721</phone>
      <email>kgalvin@kumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Cystitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be analyzed at KUMC and published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

